JP2005538934A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538934A5
JP2005538934A5 JP2003569660A JP2003569660A JP2005538934A5 JP 2005538934 A5 JP2005538934 A5 JP 2005538934A5 JP 2003569660 A JP2003569660 A JP 2003569660A JP 2003569660 A JP2003569660 A JP 2003569660A JP 2005538934 A5 JP2005538934 A5 JP 2005538934A5
Authority
JP
Japan
Prior art keywords
active substance
salt
acid
drying
eigenvalue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003569660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538934A (ja
JP4085064B2 (ja
Filing date
Publication date
Priority claimed from DE10206770A external-priority patent/DE10206770A1/de
Application filed filed Critical
Publication of JP2005538934A publication Critical patent/JP2005538934A/ja
Publication of JP2005538934A5 publication Critical patent/JP2005538934A5/ja
Application granted granted Critical
Publication of JP4085064B2 publication Critical patent/JP4085064B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003569660A 2002-02-19 2003-02-14 Cgrp拮抗剤bibn4096の塩を含有する吸入粉末の調製方法 Expired - Fee Related JP4085064B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10206770A DE10206770A1 (de) 2002-02-19 2002-02-19 Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
PCT/EP2003/001482 WO2003070753A1 (de) 2002-02-19 2003-02-14 Verfahren zur herstellung eines pulverinhalativums enthaltend ein salz des cgrp-antagonisten bibn4096

Publications (3)

Publication Number Publication Date
JP2005538934A JP2005538934A (ja) 2005-12-22
JP2005538934A5 true JP2005538934A5 (https=) 2006-02-09
JP4085064B2 JP4085064B2 (ja) 2008-04-30

Family

ID=27635111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003569660A Expired - Fee Related JP4085064B2 (ja) 2002-02-19 2003-02-14 Cgrp拮抗剤bibn4096の塩を含有する吸入粉末の調製方法

Country Status (12)

Country Link
EP (1) EP1478382B1 (https=)
JP (1) JP4085064B2 (https=)
AR (1) AR038571A1 (https=)
AT (1) ATE347900T1 (https=)
AU (1) AU2003208853A1 (https=)
CA (1) CA2476711A1 (https=)
DE (2) DE10206770A1 (https=)
ES (1) ES2279094T3 (https=)
PE (1) PE20030931A1 (https=)
TW (1) TW200400184A (https=)
UY (1) UY27673A1 (https=)
WO (1) WO2003070753A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10314617A1 (de) * 2003-04-01 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004018795A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität

Similar Documents

Publication Publication Date Title
JP2005538934A5 (https=)
JP2007502789A5 (https=)
EP1663149A2 (de) Sprühgetrocknetes, amorphes bibn 4096, verfahren zu dessen h erstellung sowie dessen verwendung als inhalativum
JP5066090B2 (ja) 金属(m1)酸化物粒子の表面に金属(m2)酸化物超微粒子をコートする方法
JP4085064B2 (ja) Cgrp拮抗剤bibn4096の塩を含有する吸入粉末の調製方法
US20030191068A1 (en) Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
JP2013512871A (ja) アミンの製造のための触媒及びアミンの製造方法
JP2013512872A (ja) 触媒及びアミンの製造方法
JP2007502789A6 (ja) 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用
HRP20010399A2 (en) Reactive crystallization method to improve particle size
JP4660745B2 (ja) 中空・球状炭酸カルシウム粒子及びその製造方法
EP0690825A1 (de) Verfahren zur katalytischen behandlung von organische und anorganische verbindungen enthaltenden abwässern, vorzugsweise aus der epichlorhydrinproduktion
JP2009522351A (ja) 無定形、無水結晶形または水和結晶形ドセタキセルの製造方法
CN108290146A (zh) 喷雾干燥丁炔二醇催化剂
CN102258945B (zh) 一种陶瓷分离膜的湿化学制备方法
CN108531023A (zh) 一种除甲醛涂料及其制备方法
CN103830868A (zh) 一种涂层功能化表面修饰剂的组合物及其制备和应用
CN107176610B (zh) 一种二氧化硅中空微球及其制备方法
JP2007502792A5 (https=)
CN106348336B (zh) 一种纳米氧化锌及其制备方法
CN101940946A (zh) 一种丙烯环氧化催化剂的制备方法
JP4085063B2 (ja) Cgrp拮抗剤bibn4096を含有する吸入粉末及びその調製方法
CN110225905A (zh) 用于保护皮肤免受重金属和甲醛影响的组合物
CN104843778A (zh) 一种亲水性介孔二氧化钛气凝胶材料的制备方法
CN116020518B (zh) 含金属的Silicate-1分子筛的球形催化剂及其成型方法和应用